Literature DB >> 18199038

Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline.

Kara B Anthony1, Neil O Fishman, Darren R Linkin, Leanne B Gasink, Paul H Edelstein, Ebbing Lautenbach.   

Abstract

Eighteen patients received tigecycline as treatment for infection due to multidrug-resistant gram-negative bacilli, including Acinetobacter baumannii and Klebsiella pneumoniae carbapenemase- and extended-spectrum beta-lactamase-producing Enterobacteriaceae. Pretherapy minimum inhibitory concentration values for tigecycline predicted clinical success. Observed evolution of resistance during therapy raises concern about routine use of tigecycline in treatment of such infections when other therapies are available.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18199038     DOI： 10.1086/526775

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  52 in total

1.  In vivo emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli.

Authors:  Teresa Spanu; Giulia De Angelis; Michela Cipriani; Barbara Pedruzzi; Tiziana D'Inzeo; Maria Adriana Cataldo; Gabriele Sganga; Evelina Tacconelli
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

2.  Tigecycline treatment of urinary tract infection and prostatitis: case report and literature review.

Authors:  Duane Bates; Mike Parkins; Robin Hellweg; Kimberly Gibson; Jennifer M Bugar
Journal:  Can J Hosp Pharm       Date:  2012-05

Review 3.  Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease.

Authors:  Yun Cai; Rui Wang; Beibei Liang; Nan Bai; Youning Liu
Journal:  Antimicrob Agents Chemother       Date:  2010-12-20       Impact factor: 5.191

4.  Tigecycline resistance can occur independently of the ramA gene in Klebsiella pneumoniae.

Authors:  Mark Veleba; Thamarai Schneiders
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

5.  In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group.

Authors:  Luis A Arroyo; Ingeborg Mateos; Verónica González; Javier Aznar
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

6.  Defining, treating and preventing hospital acquired pneumonia: European perspective.

Authors:  Antoni Torres; Santiago Ewig; Harmut Lode; Jean Carlet
Journal:  Intensive Care Med       Date:  2008-11-07       Impact factor: 17.440

7.  Superinfection during treatment of nosocomial infections with tigecycline.

Authors:  E García-Cabrera; M E Jiménez-Mejías; M V Gil Navarro; M J Gómez-Gómez; C Ortiz-Leyba; E Cordero; J Pachón
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-05-16       Impact factor: 3.267

8.  Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).

Authors:  Diana Averbuch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Christina Orasch; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

Review 9.  Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions.

Authors:  L S Tzouvelekis; A Markogiannakis; M Psichogiou; P T Tassios; G L Daikos
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

Review 10.  Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections.

Authors:  J Alexander Viehman; M Hong Nguyen; Yohei Doi
Journal:  Drugs       Date:  2014-08       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.